Moderna Inc MRNA is trading higher Monday after the U.S. Food and Drug Administration approved the Biologics License Application for SPIKEVAX to prevent COVID-19 in individuals 18 years of age and older.
SPIKEVAX, the company's mRNA Covid-19 vaccine, has now received approval from regulators in more than 70 countries. The vaccine was previously available under Emergency Use Authorization in the U.S.
"The totality of real-world data and the full BLA for Spikevax in the United States reaffirms the importance of vaccination against this virus. This is a momentous milestone in Moderna's history as it is our first product to achieve licensure in the U.S.," said Stéphane Bancel, CEO of Moderna.
Moderna is a commercial-stage biotech company. Its mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
See Also: Why Inspira Technologies Stock Is Trading Higher Today
MRNA Price Action: Moderna has traded as low as $117.34 and as high as $497.49 over a 52-week period.
The stock was up 4.86% at $167.21 at time of publication.
Photo: mufidpwt from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
